Abstract:Lingyu Zhang, 1, * Wenshu Chen, 2, * Guihui Tu, 1 Xingyong Chen, 2 Youguang Lu, 3 Lixian Wu, 1 Dali Zheng 3 1 School of Pharmacy, Fujian Medical University, University Town, Fuzhou 350122, People's Republic of China; 2 Shengli Clinical College, Fujian Medical University, Fuzhou 350001, People's Republic of China; 3 Key Laboratory of Stomatology of Fujian Province, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, 350004, People's Republic of China *These authors contributed equally to this work Correspondence: Dali Zheng Key Laboratory of Stomatology of Fujian Province, Hospital of Stomatology, Fujian Medical University, 88 Jiaotong Road, Fuzhou 350004, People's Republic of China Email dalizheng@fjmu.edu.cn Lixian Wu School of Pharmacy, Fujian Medical University, 1 Xueyuan Road, University Town, Fuzhou 350122, People's Republic of China Email 18259000966@126.com Purpose: Currently, the clinical benefits of tea polyphenols have contributed to the development of efficient systemic delivery systems with adequate bioavailability and stability. In this study, we aimed to establish a nanoparticle model to overcome the shortcomings of epigallocatechin gallate (EGCG) in the treatment of lung cancer. Materials and Methods: Poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) loaded with EGCG were prepared by the oil-in-water emulsion solvent evaporation technique. The characteristics of NPs, entrapment efficiency, and in vitro release were systematically evaluated. The cellular uptake, cytotoxic activity, and the effect of the formulation on cellular apoptosis of free-from EGCG and the NPs were compared. The interaction between protein-NF-κB and EGCG was detected by bio-layer interferometry (BLI). NF-κB signaling was evaluated by Western blotting and q-RT-PCR. The efficacy of the optimized nanoformulation was evaluated using a patient-derived tumor xenograft (PDX) model. Results: EGCG-loaded NPs (175.8± 3.8 nm in size) demonstrated its optimal efficacy, with approximately 86.0% of encapsulation efficiency and 14.2% of loading efficiency. Additionally, EGCG-encapsulated PLGA-NPs offered a 3-4-fold dose advantage compared to free EGCG in terms of exerting antiproliferative effects and inducing apoptosis at lower doses (12.5, 25 μM). Molecular interaction assays demonstrated that EGCG binds to NF-κB with high affnity (KD=4.8× 10 − 5 M). EGCG-NPs were more effective at inhibiting NF-κB activation and suppressing the expression of NF-κB-regulated genes than free EGCG. Furthermore, EGCG-NPs showed superior anticancer activity in the PDX model than free EGCG. Conclusion: These findings indicated that the prepared EGCG-NPs were more effective than free EGCG in inhibiting lung cancer tumors in the PDX model. Keywords: anticancer, tea polyphenol, nanoparticles, NF-κB

Epigallocatechin Gallate-Β-lactoglobulin Nanoparticles Improve the Antitumor Activity of EGCG for Inducing Cancer Cell Apoptosis

Protein Phosphatase-2A is a Target of Epigallocatechin-3-Gallate and Modulates P53-Bak Apoptotic Pathway

New Epigallocatechin Gallate (Egcg) Nanocomplexes Co-Assembled With 3-Mercapto-1-Hexanol And Beta-Lactoglobulin For Improvement Of Antitumor Activity

(-)-Epigallocatechin-3-gallate Induces Non-Apoptotic Cell Death in Human Cancer Cells Via Ros-Mediated Lysosomal Membrane Permeabilization

Enhanced Chemotherapeutic Efficacy of PLGA-Encapsulated Epigallocatechin Gallate (EGCG) Against Human Lung Cancer

Inhibitory Effects of (-)-epigallocatechin-3-gallate on Melanogenesis in Ultraviolet A-Induced B16 Murine Melanoma Cell

Inhibitory Effects of (−)-Epigallocatechin-3-gallate on Esophageal Cancer

Potential Effect of EGCG on the Anti-Tumor Efficacy of Metformin in Melanoma Cells

A Component of Green Tea, (-)-epigallocatechin-3-gallate, Promotes Apoptosis in T24 Human Bladder Cancer Cells Via Modulation of the PI3K/Akt Pathway and Bcl-2 Family Proteins

Targeting Glycolysis with Epigallocatechin-3-Gallate Enhances the Efficacy of Chemotherapeutics in Pancreatic Cancer Cells and Xenografts

Tumor-Homing Cell-Penetrating Peptide Linked to Colloidal Mesoporous Silica Encapsulated (-)-epigallocatechin-3-gallate As Drug Delivery System for Breast Cancer Therapy in Vivo.

Enhanced anticancer activity of (–)-epigallocatechin-3-gallate (EGCG) encapsulated NPs toward colon cancer cell lines

Molecular mechanism of epigallocatechin-3-gallate in human esophageal squamous cell carcinoma in vitro and in vivo.

The Epigenetic Modification of Epigallocatechin Gallate (EGCG) on Cancer

Epigallocatechin Gallate, the Main Ingredient of Green Tea Induces Apoptosis in Breast Cancer Cells.

Epigallocatechin-3-gallate promotes apoptosis in human breast cancer T47D cells through down-regulation of PI3K/AKT and Telomerase

Preparation and characterization of (−)-Epigallocatechin-3-gallate (EGCG)-loaded nanoparticles and their inhibitory effects on Human breast cancer MCF-7 cells

Anti-melanogenic effects of epigallocatechin-3-gallate (EGCG), epicatechin-3-gallate (ECG) and gallocatechin-3-gallate (GCG) via down-regulation of cAMP/CREB /MITF signaling pathway in B16F10 melanoma cells

Investigation of folate-modified EGCG-loaded thermosensitive nanospheres inducing immunogenic cell death and damage-associated molecular patterns in hepatocellular carcinoma

In Vitro and in Vivo Study of Epigallocatechin-3-gallate-induced Apoptosis in Aerobic Glycolytic Hepatocellular Carcinoma Cells Involving Inhibition of Phosphofructokinase Activity

Improved Stability and Targeted Cytotoxicity of Epigallocatechin-3-Gallate Palmitate for Anticancer Therapy.